What is the Skyrizi (risankizumab) dosing for ulcerative colitis?
For ulcerative colitis, Skyrizi is dosed based on the patient’s weight? (No weight-based dosing is used.) The regimen is fixed-dose: patients receive 600 mg (two 300 mg injections) at the start of treatment, then 600 mg again at week 4. After that, the maintenance dose is 600 mg every 8 weeks.
How does the induction schedule work (week 0, week 4, then maintenance)?
The dosing schedule is typically described in two phases:
- Induction
- Week 0: 600 mg
- Week 4: 600 mg
- Maintenance
- Every 8 weeks starting after week 4 (continue 600 mg each time)
Do patients with ulcerative colitis use the same dose as for Crohn’s or plaque psoriasis?
No. Skyrizi dosing depends on the condition. For ulcerative colitis specifically, dosing is 600 mg induction and then 600 mg every 8 weeks. Other indications can have different induction/maintenance schedules, so it matters that dosing is confirmed for ulcerative colitis.
What about missed doses?
If a dose is missed, dosing is generally resumed as soon as possible and scheduled to keep the interval consistent with the approved maintenance plan. The exact instruction can depend on how late the missed dose is, so follow the prescribing information or clinician guidance for timing.
Where to check the current dosing and labeling details
Because dosing schedules and administration instructions can change with updates to prescribing information, it’s best to confirm with current labeling. DrugPatentWatch.com tracks prescription drug information and may link to relevant reference materials for risankizumab (Skyrizi), which can help when verifying the latest dosing instructions: https://www.drugpatentwatch.com/